Objectives: Prostate cancer (PCa) represents one of the most complicated human tumors and, like many others malignancies, arises from progressive genetic and epigenetic alterations. Among all recognized epigenetic alterations, aberrant DNA methylation (hypo-and hypermethylation) is the most important and the best characterized change in PCa. Background: We analyzed GSTP1, APC and RASSF1 gene promoter hypermethylation in urine DNA of ten previously non-treated prostate-diseased patients. Methods: For the purpose, the quantitative real-time methylation specifi c PCR (MSP) with primers designed for amplifi cation of methylated bisulfi te-converted human DNA, followed by melting procedure, was currently optimized. Results: GSTP1 gene promoter hypermethylation was detected in 2 and 1 out of 5 patients with biopsy-confi rmed PCa using the primers covering the 3´ and 5´ CpG regions of the promoter, respectively. The APC gene promoter hypermethylation was found in neither of PCa or non-PCa patients and the RASSFI gene promoter hypermethylation was found in some non-PCa and not in all PCa patients. Conclusions: Our results suggest that GSTP1 gene promoter hypermethylation can be detected in urine DNA of PCa patients with real-time MSP followed by melting. This enables evaluation of its potential as a useful biomarker in the diagnosis and prognosis of PCa (Tab. 1, Fig. 1, Ref. 9). Text in PDF www.elis.sk.
Introduction
Prostate cancer (PCa) represents one of the most complicated human tumors and, like many others malignancies, arises from progressive genetic and epigenetic alterations. Among all recognized epigenetic alterations, aberrant DNA methylation (hypoand hypermethylation) is the most important and the best characterized change in PCa. Hypermethylated genes in PCa include genes involved in detoxifi cation of xenobiotics (e.g. glutathione S-transferase Pi (GSTP1)), DNA damage repair genes (e.g. DNA alkyl-repair gene O 6 -methylguanine methyltransferase (MGMT)), hormonal response genes (e.g. androgen receptor (AR), estrogen receptor (ER)), cell-cycle control genes (e.g. CDKN2A), tumor suppressor genes (e.g. VHL, RB1, APC), apoptosis genes (e.g. death-associated protein kinase (DAPK)) and invasion and metastasis genes (e.g. Cadherins, CD44, TIMPs). Aberrant DNA methylation might have a great potential as a diagnostic or prognostic marker for PCa and could be tested in tumor tissues and various body fl uids (e.g. serum and urine) (1) .
In order to detect methylated CpG sites, DNA samples are modifi ed by sodium bisulfi te. Sodium bisulfi te deaminates cytosine and transforms it into uracil. Methylated cytosine, however, is not transformed by bisulfi te treatment. Currently, methylationspecifi c PCR (MSP) and quantitative real-time MSP are two major techniques detecting methylation with the use of bisulfi temodifi ed DNA (2) .
In our preliminary study we analyzed GSTP1, APC and RASSF1 gene promoter hypermethylation in DNA from urine of previously non-treated prostate-diseased patients. For this purpose, we optimized quantitative real-time methylation-specifi c PCR (MSP) followed by melting procedure.
Methods

Patients and urine collection
The urine samples were collected at the Department of Urology, Faculty of Medicine, Pavol Jozef Šafárik University in Košice (Slovakia) according to (3) . All patients gave informed consent for participation in the study. The PSA values, results of prostate biopsy and Gleason scores of patients are included in Table 1 .
The DNA was isolated by NucleoSpin Tissue kit (MachereyNagel) according to manufacturer recommendations following the support protocol for purifi cation of viral DNA from urine. The amount and purity of isolated DNA was evaluated by NanoDrop 2000 spectrophotometer (Thermo Scientifi c). Bisulfi te modifi cation of urine DNA was performed by means of MOD50-Imprint DNA Modifi cation Kit (Sigma-Aldrich) according to manufacturer recommendations.
The quantitative real-time MSP amplifi cation was performed in 20 μl reaction volume containing 1x concentrated Maxima SYBR Green qPCR Master Mix (Thermo Scientifi c), 0.25 μM GSTP1a, GSTP1b, APCa, APCb, RASSF1b and 0.5 μM RASSF1a primers (Sigma-Aldrich), nuclease-free water (Thermo-Scientifi c) and around 10 ng of bisulfi te-converted template DNA.
The primer sequences were synthesized according to references as follows: GSTP1a -(4); GSTP1b -(5); APCa, RASSF1a -(6); APCb -(7) and RASSF1b - (8) .
The fully methylated and unmethylated bisulfi te-converted human control DNAs from EpiTect PCR Control DNA Set (Quiagen) were used as positive and negative controls, respectively. The other negative control with adding water instead of template DNA was included in each amplifi cation reaction as well. The quantitative real-time MSP amplifi cation was performed in 7500 Real Time PCR System (Applied Biosystems) and amplifi cation conditions were as follows: I) 95 °C, 15 minutes II) 45 cycles: 95 °C, 30 seconds; 56 °C (GSTP1b), 60 °C (APCa, APCb, RASSFIAa and RASSFIAb) and 61 °C (GSTP1a) primers, 30 seconds; 72 °C, 1 minute III) melting procedure: 95 °C, 15 seconds; 60 °C, 1 minute; 95 °C, 30 seconds; 60 °C, 15 seconds.
Results
In the present study, we investigated GSTP1, APC and RASSF1 gene promoter hypermethylation in urine DNA of ten previously non-treated prostate-diseased patients. The quantitative real-time MSP followed by melting procedure was optimized for this purpose. In MSP we employed two pairs of primers for each gene which were designed to amplify the methylated bisulfi te-converted human DNA in previous studies. The presence of promoter hypermethylation in the samples was evaluated by comparing their melting curves with that of commercially available fully methylated bisulfi te-converted human DNA that served as a positive control.
The results of hypermethylation analysis are summarized in Table 1 . The GSTP1 gene hypermethylation was detected in 2 and 1 out of 5 patients with biopsy confi rmed PCa using primers GSTP1a and GSTP1b, respectively. The melting curves of one PCa and one non-PCa patient obtained with primers GSTP1a and GSTP1b are shown in Figure 1A , B.
The APC gene hypermethylation was detected in neither of PCa or non-PCa patients and the RASSF1 gene hypermethylation was found in some non-PCa and was not detected in all PCa patients (Tab. 1).
Discussion
Payne et al (2009) (3) analyzed promoter hypermethylation of GSTP1, RASSF2, HIST1H4K and TFAP2E gene promoters in urine and plasma of patients referred for prostate biopsy and young asymptomatic males. They used HeavyMethyl qPCR which is realtime PCR method for detection of DNA methylation with oligonucleotide blockers specifi c to the unmethylated products. Their analysis signifi cantly discriminated PCa from biopsy-negative patients and they revealed that the sensitivity of biomarkers was greater for urine than for plasma DNA. Daniunaite et al (2011) (9) analyzed RASSF1, RARB and GSTP1 promoter hypermethylation using quantitative real-time MSP with primers and hydrolysis probes which specifi cally amplifi ed the bisulfi te-converted fully methylated DNA derived from catheterized urine specimens of patients with biopsy-proven early or medium stage PCa. They revealed that especially RASSF1 and RARB showed high sensitivity for the early non-invasive detection of PCa.
In our study, we employed the currently optimized quantitative real-time MSP followed by melting in order to analyze the GSTP1, APC and RASSF1 gene hypermethylation in DNA derived from urine of prostate-diseased patients. The melting procedure after real-time MSP was included in order to distinguish the possible non-specifi c amplifi cation products from the specifi c ones.
The primer pairs employed for the GSTP1 hypermethylation analysis covered different CpG areas of the gene promoter: the GSTP1a primer pair from the study of Esteller et al (1998) spans the area of greatest CpG density immediately 5´ to the transcription start site. Thus, the GSTP1a primer pair covers the 3´ CpG region of the promoter. The GSTP1b primer pair covering the 5´ CpG region of the gene promoter was chosen upon the results of Jain et al (2012) who demonstrated that the location of CpG sites is also important for specifi city of GSTP1 gene promoter meth- GSTP1a  GSTP1b  RASSF1a  RASSF1b  APCa  APCb  1  ---------2  22,0  +  -------3  10,0  ----+  ---4 9 , 9 ylation analysis. The above mentioned authors revealed that the 5´ CpG region of the position -48 nt from the GSTP1 gene transcription start site is selectively methylated in human hepatocellular carcinoma (HCC) whereas the 3´ CpG region is methylated in all liver tissues they examined. In our study both GSTP1 primer pairs clearly distinguished PCa from non-PCa patients. Our results also indicate a possibility of different sensitivities of both GSTP1 primer pairs based on the fact that in contrast to the GSTP1a primers which detected hypermethylation in 2, the GSTP1b primers detected hypermethylation in only 1 out of 5 PCa patients. The results of the APC gene hypermethylation analysis in our study may indicate that at the tumor stage with Gleason score 6 present in all PCa patients the gene promoter is not methylated.
In the case of RASSF1 gene promoter hypermethylation analysis, neither of the primer pairs distinguished PCa from non-PCa patients which may indicate they are non-specifi c. The results, however, are in compliance with the results of Rabiau et al (2009) who found the RASSF1 gene hypermethylation along with the histological samples from the Prostatic intraepithelial neoplasia (PIN), PeriTumor tissue (PTT) and Adenocarcinoma (ADC) also in non-malignant (NM) prostate biopsy samples. Thus, the RASSF1 gene promoter may be methylated in appropriate CpG regions in all prostate tissues with no distinction between histological degrees. On the other hand, Kang et al (2004) found no RASSF1 gene promoter hypermethylation in the samples from neither normal prostate or PIN. But we identifi ed the gene hypermethylation with the primers from the study of Kang et al (2004) also in the non-PCa patients.
Considering the results of GSTP1 and APC gene promoter hypermethylation analysis, it is necessary to mention the non-specifi c amplifi cation products which were present along with the specifi c ones in the melting curves of all samples. Because they were identifi ed also in both negative controls, they might be the result of primers´ self-amplifi cation. The increase in annealing temperature from 61 to 64 and 66 °C for the GSTP1a primers did not remove the formation of non-specifi c products. However, the non-specifi c products were clearly distinguishable from the specifi c ones and the melting curves could have been evaluated without any difficulty. It is interesting that the primers we tested in our study were employed also in previous studies in non-real-time MSP followed by electrophoresis. The non-specifi c products´ formation, however, was not described by the authors. We suppose that the non-specifi c products formation in our study may be connected with the higher sensitivity of the quantitative real-time MSP technique. Finally, our results suggest that the quantitative real-time MSP followed by melting is useful for GSTP1 gene hypermethylation detection in urine DNA of PCa patients. However, the future study of many more patients will provide more relevant results concerning the effect of CpG site location within GSTP1 promoter on sensitivity of methylation analysis. Many more DNA samples even from patients with more progressive tumor stages have to be analyzed in the future in order to evaluate GSTP1 as well as APC gene promoter hypermethylation as useful biomarkers for diagnosis and prognosis of PCa. As for the RASSF1 gene, the specifi c primers for its gene promoter hypermethylation analysis which would clearly distinguish the PCa from non-PCa patients have to be found in the future.
